1. OFATUMUMAB WITH IVAC FOR DLBCL PATIENTS WHO FAILED R‐CHOP AND WERE NOT CANDIDATES FOR HIGH‐DOSE THERAPY AND ASCT ‐ PHASE 2 TRIAL OF THE POLISH LYMPHOMA RESEARCH GROUP (PLRG‐8). (12th June 2019) Authors: Paszkiewicz‐Kozik, E.; Michalski, W.; Taszner, M.; Knopińska‐Posłuszny, W.; Mordak‐Domagała, M.; Najda, J.; Borawska, A.; Romejko‐Jarosińska, J.; Chełstowska, M.; Świerkowska, M.; Dąbrowska‐Iwanicka, A.; Malenda, A.; Druzd‐Sitek, A.; Konecki, R.; Kuniega, B.; Osowiecki, M.; Ostrowska, B.; Szpila,... Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 436 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. R‐ DAEPOCH as a first line treatment for high grade B cell lymphoma and diffuse large B cell lymphoma with unfavorable features. (June 2017) Authors: Romejko‐Jarosinska, J.; Rymkiewicz, G.; Paszkiewicz‐Kozik, E.; Dabrowska‐Iwanicka, A.P.; Borawska, A.; Domanska‐Czyz, K.; Konecki, R.; Kotarska, M.; Osowiecki, M.; Ostrowska, B.; Poplawska, L.; Swierkowska‐Czeneszew, M.; Szymanski, M.; Targonski, Ł.; Blachnio, K.; Bystydzienski, Z.; Grygalewicz, ... Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 335 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. R‐CHOP is not effective regimen in CD5(+)DLBCL diagnosed by flow‐cytometry/immunohistochemistry, karyotype and BCL2/BCL6 status and expression. (June 2017) Authors: Rymkiewicz, G.; Romejko‐Jarosinska, J.; Paszkiewicz‐Kozik, E.; Błachnio, K.; Kotarska, M.; Bystydzienski, Z.; Domanska‐Czyz, K.; Ostrowska, B.; Dabrowska‐Iwanicka, A.; Woroniecka, R.; Grygalewicz, B.; Osowiecki, M.; Jastrzebska, A.; Walewski, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 333 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗